Disparities in the quantity and percentage of the documented psychiatric AEs among different GLP-1 RAs could potentially be associated with factors such as their duration in the market (e.g., more time for AEs to be reported into FAERS for medications that have been available for longer), clinical utilization, and specific drug characteristics
Semaglutide is a GLP-1 receptor agonist, which means that it mimics the effects of a naturally occurring hormone in the body called GLP-1
This trial is critical because it evaluates retatrutide's dual benefits: weight reduction and glycemic control
Sci Transl Med 2024;16:eadk4908.ArticlePubMed 77
Giaconi JA, Stone KL, Pedula KL, Ensrud KE, Cauley JA, Hochberg MC, Coleman AL
Inadequate dosages may lead to higher than normal blood sugar levels, which can affect major body organs over time if unchecked